Your browser doesn't support javascript.
loading
Cardiovascular predictors of mortality and exacerbations in patients with COPD.
Alter, Peter; Lucke, Tanja; Watz, Henrik; Andreas, Stefan; Kahnert, Kathrin; Trudzinski, Franziska C; Speicher, Tim; Söhler, Sandra; Bals, Robert; Waschki, Benjamin; Welte, Tobias; Rabe, Klaus F; Vestbo, Jørgen; Wouters, Emiel F M; Vogelmeier, Claus F; Jörres, Rudolf A.
Afiliação
  • Alter P; Department of Medicine, Pulmonary and Critical Care Medicine, University of Marburg (UMR), Member of the German Center for Lung Research (DZL), Baldingerstrasse 1, 35033, Marburg, Germany. Alter@uni-marburg.de.
  • Lucke T; Institute and Outpatient Clinic for Occupational, Social and Environmental Medicine, University Hospital, LMU Munich, Comprehensive Pneumology Center Munich (CPC-M), Member of the German Center for Lung Research (DZL), Munich, Germany.
  • Watz H; Airway Research Center North (ARCN), Member of the German Center for Lung Research (DZL), Pulmonary Research Institute at LungenClinic Grosshansdorf, Grosshansdorf, Germany.
  • Andreas S; LungClinic Immenhausen and Department of Cardiology and Pneumology, University Medical Center Göttingen, Member of the German Center for Lung Research (DZL), Göttingen, Germany.
  • Kahnert K; Department of Internal Medicine V, University Hospital, LMU Munich, Comprehensive Pneumology Center Munich (CPC-M), Member of the German Center for Lung Research (DZL), Munich, Germany.
  • Trudzinski FC; Department of Pneumology and Critical Care Medicine, Thoraxklinik, University of Heidelberg, Translational Lung Research Center Heidelberg (TLRC-H), Member of the German Center for Lung Research (DZL), Heidelberg, Germany.
  • Speicher T; Department of Medicine, Pulmonary and Critical Care Medicine, University of Marburg (UMR), Member of the German Center for Lung Research (DZL), Baldingerstrasse 1, 35033, Marburg, Germany.
  • Söhler S; Department of Medicine, Pulmonary and Critical Care Medicine, University of Marburg (UMR), Member of the German Center for Lung Research (DZL), Baldingerstrasse 1, 35033, Marburg, Germany.
  • Bals R; Department of Internal Medicine V - Pulmonology, Allergology, Intensive Care Medicine, Saarland University Hospital, Homburg, Germany.
  • Waschki B; Department of Pneumology, Hospital Itzehoe, Airway Research Center North (ARCN), Member of the German Center for Lung Research (DZL), LungenClinic Grosshansdorf, Grosshansdorf, Germany.
  • Welte T; Department of Cardiology, University Heart Center Hamburg, Hamburg, Germany.
  • Rabe KF; Clinic for Pneumology, Hannover Medical School, Member of the German Center for Lung Research (DZL), Hannover, Germany.
  • Vestbo J; LungenClinic Grosshansdorf and Department of Medicine, Airway Research Center North (ARCN), Member of the German Center for Lung Research (DZL), Christian-Albrechts University, Kiel, Kiel/Grosshansdorf, Germany.
  • Wouters EFM; Division of Infection, Immunity and Respiratory Medicine, University of Manchester, Manchester, UK.
  • Vogelmeier CF; Department of Respiratory Medicine, Maastricht University Medical Centre, Maastricht, The Netherlands.
  • Jörres RA; Ludwig Boltzmann Institute for Lung Health, Vienna, Austria.
Sci Rep ; 12(1): 21882, 2022 12 19.
Article em En | MEDLINE | ID: mdl-36536050
In chronic obstructive pulmonary disease (COPD), comorbidities and worse functional status predict worse outcomes, but how these predictors compare with regard to different outcomes is not well studied. We thus compared the role of cardiovascular comorbidities for mortality and exacerbations. Data from baseline and up to four follow-up visits of the COSYCONET cohort were used. Cox or Poisson regression was employed to determine the relationship of predictors to mortality or mean annual exacerbation rate, respectively. Predictors comprised major comorbidities (including cardiovascular disease), lung function (forced expiratory volume in 1 s [FEV1], diffusion capacity for carbon monoxide [TLCO]) and their changes over time, baseline symptoms, exacerbations, physical activity, and cardiovascular medication. Overall, 1817 patients were included. Chronic coronary artery disease (p = 0.005), hypertension (p = 0.044) and the annual decline in TLCO (p = 0.001), but not FEV1 decline, were predictors of mortality. In contrast, the annual decline of FEV1 (p = 0.019) but not that of TLCO or cardiovascular comorbidities were linked to annual exacerbation rate. In conclusion, the presence of chronic coronary artery disease and hypertension were predictors of increased mortality in COPD, but not of increased exacerbation risk. This emphasizes the need for broad diagnostic workup in COPD, including the assessment of cardiovascular comorbidity.Clinical Trials: NCT01245933.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença da Artéria Coronariana / Doença Pulmonar Obstrutiva Crônica / Hipertensão Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença da Artéria Coronariana / Doença Pulmonar Obstrutiva Crônica / Hipertensão Idioma: En Ano de publicação: 2022 Tipo de documento: Article